Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Shares Outstanding for 10 consecutive years, with $108.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.75% to $108.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.3 million through Dec 2025, up 1.75% year-over-year, with the annual reading at $108.3 million for FY2025, 1.75% up from the prior year.
  • Shares Outstanding hit $108.3 million in Q4 2025 for Rocket Pharmaceuticals, roughly flat from $108.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $108.3 million in Q4 2025 to a low of $62.0 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $84.2 million across 5 years, with a median of $85.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding: surged 32.88% in 2023 and later grew 1.08% in 2024.
  • Year by year, Shares Outstanding stood at $64.5 million in 2021, then rose by 22.66% to $79.1 million in 2022, then rose by 14.1% to $90.3 million in 2023, then grew by 17.91% to $106.5 million in 2024, then grew by 1.75% to $108.3 million in 2025.
  • Business Quant data shows Shares Outstanding for RCKT at $108.3 million in Q4 2025, $108.2 million in Q3 2025, and $107.9 million in Q2 2025.